Phase 3 Drug Priced for Zero

🌾 Welcome to StableBread's Newsletter!

Would you put money into a company that earns no revenue, just ran a 1:20 reverse split, raised cash to keep the lights on, and got bumped off the Nasdaq down to the OTCQB market?

For most investors, that's an instant pass. It fails nearly every screen, and in biotech that exact sequence usually follows a failed trial or an FDA rejection—the kind of setback that brings heavy dilution, lost institutional interest, and a fight to stay public.

That's how the market treats Reviva Pharmaceuticals (OTCQB: RVPH) today, valuing the whole company at ~$10M, less than the $22.2M of cash in its bank account.

But the company underneath it owns a schizophrenia drug that has cleared two efficacy trials and a full year of safety testing. On Reviva's own filings, that drug outperformed Caplyta, a rival schizophrenia pill Johnson & Johnson (JNJ) bought for $14.6B in January 2025.

And the company is now extending the drug's patent out to 2046, which is what turns it into the kind of drug big pharma pays billions for.

Below, I’ll discuss what the drug has shown, why the stock collapsed, what has to go right, and whether I'm opening a position.

Reviva is a clinical-stage biotech, which means it sells nothing and earns no revenue. It runs on money raised from investors, spends it on research, and lives or dies on whether its experimental drug reaches the market.

Reviva runs lean, with ~14 employees and offices in Cupertino and Bangalore, led by founder and CEO Dr. Laxminarayan Bhat.

It has two drugs, both discovered in-house. One of them carries the whole story.

That drug is brilaroxazine (RP5063), a once-daily pill for schizophrenia. It rebalances serotonin and dopamine signaling, and it also acts on receptors tied to neuroinflammation, a factor researchers increasingly connect to the disease.

The goal is broad symptom control with fewer side effects than today's antipsychotics.

The second drug, RP1208, is a much earlier preclinical compound for depression and obesity. It's years away from human testing, so I'm leaving it out of this analysis.

Schizophrenia is brilaroxazine's lead market, projected to reach $15.9B by 2035 and affecting ~24 million people worldwide. It's a chronic, lifelong illness, and the drugs that treat it have long disappointed.

Most existing antipsychotics force a trade-off. They quiet symptoms but bring weight gain, movement disorders, sedation, and hormonal side effects, and about a third of patients don't respond at all. Patients struggle to stay on drugs that make them feel that way.

That gap, a large market served by drugs people can't stay on, is the opening brilaroxazine is built for. The same molecule has also run early studies or holds patents in bipolar disorder, major depression, ADHD, and two rare lung diseases.

Schizophrenia is just the first stop. The bigger prize is developing the same molecule across those adjacent markets, several of them as large as schizophrenia itself.

Reviva breached Nasdaq's $1.00 minimum bid in May 2025 and never recovered. It then ran a 1-for-20 reverse split in March 2026.

The stock slid back under $1.00 anyway, and on May 14, 2026 it dropped from the Nasdaq to the OTCQB, a lower-tier market with thinner trading and far less institutional ownership.

This usually means a company spiraling toward zero, and the market has priced the stock as such:

Currently, the stock trades near $0.63/share, at a ~$10M market cap. Against that, Reviva ended its last quarter with $22.2M of cash, almost no debt, and $17.4M of book value.

So the market values the entire company under its cash and book value alike… Just look at enterprise value (market cap minus net cash), which sits near negative $12M. Strip out the cash, and the market is assigning the drug a value below zero.

In other words, the market is handing you the cash at a discount and throwing in brilaroxazine, the trial data, and the patents for free.

The burn runs only ~$2M a quarter now, but it climbs once the company's next trial starts enrolling in Q3 2026. That trial and the approval filing cost $50-55M against the $22.2M on hand, so ~$30M still has to be raised, and the cash only carries the company into early 2027 (more on this later).

So the company isn't about to vanish, but the cash gets spent and shareholders get diluted over time, meaning the floor erodes if nothing goes right.

The upside runs the other way. If the drug is worth anything close to the $8.7-14.6B that J&J, Bristol-Myers, and AbbVie recently paid for schizophrenia and CNS drugmakers, you're paying only $10M.

Brilaroxazine's clinical record runs deeper than a sub-dollar stock suggests. It has completed three studies in schizophrenia, dosing ~900 patients in total:

PANSS is the field's standard yardstick, the scale regulators rely on to judge whether an antipsychotic works. A 10-point separation from placebo, holding and deepening across a year, is a strong showing.

Safety is where the drug makes its case. Across a year of dosing, brilaroxazine showed:

That profile drives the commercial case. Schizophrenia patients relapse when they stop taking their medication, and they stop when the side effects become unbearable.

A drug patients will actually stay on is obviously worth more than one they quit.

Brilaroxazine's discontinuation rate ran ~36% over the year-long study, against historical rates as high as 80% for older drugs.

It also delivered on negative symptoms, the social withdrawal and flat affect that current drugs barely touch, with the effect confirmed by a vocal biomarker published in January 2026 in the journal Biological Psychiatry.

Then there's the comparison that frames the whole opportunity:

On Reviva's own cross-trial numbers, brilaroxazine separated from placebo by 10.1 PANSS points versus 4.2 for Caplyta, with a lighter side-effect load.

Caplyta is no cautionary tale. It missed its second Phase 3 outright, never beating placebo on the main endpoint, yet still won approval and sold to J&J for $14.6B.

Cross-trial comparisons come with caveats, since patient groups and trial designs differ. Still, brilaroxazine's data stands at least even with a drug that just changed hands for eleven figures.

In December 2025, the FDA told Reviva to run one more Phase 3 trial before filing brilaroxazine for approval. The stock fell hard on the news, and that reaction sits at the center of the mispricing.